Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. (2019)
Attributed to:
Phase I/II trial of lentiviral vector mediated gene therapy for Adenosine Deaminase deficiency
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jaci.2018.08.024
PubMed Identifier: 30194989
Publication URI: http://europepmc.org/abstract/MED/30194989
Type: Journal Article/Review
Volume: 143
Parent Publication: The Journal of allergy and clinical immunology
Issue: 3
ISSN: 0091-6749